Researchers create an analytic tool that opens a new frontier of cancer discovery

Google+ Pinterest LinkedIn Tumblr +

Gene coding regions constitute 2% of the human genome.

St. Jude Children’s Research Hospital scientists have developed a computational tool to identify alterations that drive tumour formation in the remaining 98% of the genome.

The method will aid discovery of oncogenes and advances in precision medicine for children and adults with cancer.

The approach, detailed today in the journal Nature Genetics, is called cis-expression or cis-X.

Researchers developed the innovative analytic method to identify novel pathogenic variants and oncogenes activated by such variants in regulatory noncoding DNA of patient tumours.

Cis-X works by identifying abnormal expression of tumour RNA.

Investigators analysed leukaemia and solid tumours and demonstrated the power of the approach.

Noncoding DNA, which does not encode genes, makes up 98% of the human genome.

However, growing evidence suggests that more than 80% of the noncoding genome is functional and may regulate gene expression.

Population studies have identified variants in noncoding DNA that are associated with an elevated cancer risk.

But only a small number of noncoding variants in tumour genomes that contribute to tumour initiation have been discovered.

Finding these variants required whole genome sequencing analysis of a large number of tumour samples.

“Cis-X is a fundamental change from existing approaches that require thousands of tumour samples and only identify noncoding variants that happen recurrently,” said Jinghui Zhang, Ph.D., St. Jude Department of Computational Biology chair. She and Yu Liu, Ph.D., previously of St. Jude and now of Shanghai Children’s Medical Center, are the corresponding authors. Liu is also a first author.

“By using aberrant gene transcription to reveal the function of noncoding variants, we developed cis-X to enable discovery of noncoding variants driving cancer in individual tumour genomes,” Zhang said. “Identifying variants that lead to dysregulation of oncogenes can expand the scope of the precision medicine to noncoding regions for identifying therapeutic options to suppress aberrantly activated oncogenes in tumours.”

Inspiration

Cis-X was inspired by a 2014 Science paper from Thomas Look, M.D., of Dana-Farber Cancer Institute and his colleagues.

Look is a co-author of the current paper.

Working in cell lines, Look’s team identified noncoding DNA variants responsible for abnormal activation of an oncogene (TAL1) that led to T-cell acute lymphoblastic leukaemia (T-ALL).

The research prompted Zhang to pursue her long-standing interest in examining variations in expression of each copy of a gene.

Cis-X works by searching for genes with altered expression in two ways.

Researchers used whole genome and RNA sequencing to find genes that are expressed on just one chromosome and expressed at aberrantly high levels.

“It can be noisy when analysing the imbalance of gene expression between alleles,” Liu said. “This analysis used a novel mathematical model that makes cis-X a robust tool for discovery.”

Cis-X then searches for the cause of the abnormal expression by looking for alterations in regulatory regions of noncoding DNA within a 3D genome architecture.

“The approach mimics the way the variants work in living cells,” Liu said.

The alterations include changes such as chromosomal rearrangements and point mutations.

“Few functional noncoding variations happen at high recurrence, but they are important drivers of tumour initiation and progression,” Zhang said. “Without identifying the noncoding variant, we may not have the full picture of what caused the cancer.”

Confirmation

Researchers used cis-X to analyze the cancer genomes of 13 T-ALL patients with the data generated as a collaboration between St. Jude and Shanghai Children’s Medical Center.

The algorithm identified known and novel oncogene-activating noncoding variants as well as a possible new T-ALL oncogene, PRLR.

Investigators also showed the method worked in adult and paediatric solid tumours, including neuroblastoma, a childhood cancer of immature nerve cells.

Solid tumours posed a greater analytic challenge.

Unlike leukaemia, solid tumours often have an abnormal number of chromosomes that are not uniformly distributed in the tumour.

“Cis-X offers a powerful new approach for investigating the functional role of noncoding variants in cancer, which may expand the scope of precision medicine to treat cancer caused by such variants,” Zhang said.

Cis-X software is publicly available at no cost to researchers through GitHub software repository, St. Jude Cloud and Zhang’s laboratory page.


Source: St. Jude Children’s Research Hospital

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.